Navigation Links
Tim in Medical Technology

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

...hrough in CF patients' arduous treatment burden , and are looking forward to seeing the Phase II results and moving to Phase III soon afterward," said tim Whitten, Transave's President and Chief Executive Officer. "We are grateful for the continued support of the CF Foundation as we strive to improve tr...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

...ry endpoint was to evaluate response rate according to RECIST. "We are encouraged by these data of BAY 73-4506," said lead investigator Professor tim Eisen, F.R.C.P., PhD, of Addenbrooke's Hospital at the University of Cambridge , UK. "These data provide a rationale to move into a Phase III trial ...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

...in Hereditary Angioedema In an abstract entitled, 'When Should Prophylactic Therapy be Considered for Hereditary Angioedema?', Dr. tim Craig, et al. described how a literature review, guideline analysis from other countries, expert panel meeting, and consensus development were conduct...

Pharmatek's Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds

...tek to expand our development and manufacturing services to include highly potent and cytotoxic compounds, and do it in the safest possible way," says tim Scott, President of Pharmatek Laboratories. "The results from extensive facility testing exceeded Pharmatek's expectations for the safe handling of ca...

Ancestry.com DNA Testing Reveals 'Roots' Author's Scottish Ancestry

...supplying the recipient with rich detail about their ancient ancestry. "This is a perfect example of what a simple cheek swab can achieve," said tim Sullivan, CEO of The Generations Network, Inc., parent company of Ancestry.com. "DNA testing uses science in a way that enables people to discover the...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

...are pleased that we were able to capitalize on an opportunity to further strengthen our balance sheet by reducing our debt at reasonable prices," said tim Barabe, Senior Vice President and Chief Financial Officer, HGS. "Our cash position remains strong and is sufficient to take us through the availabili...

WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System

... (investors) 415-675-7400 sdiaz@vidacommunication.com " target="_new"> sdiaz@vidacommunication.com tim Brons (media) 415-675-7400 tbrons@vidacommunication.com " target="_new"> tbrons@vidacommunication.com ...

Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology

...which provides a growing and important revenue source for the company. Dr tim Allsopp, Chief Scientific Officer of Stem Cell Sciences, commented, "This p...e contact: Stem Cell Sciences plc (United Kingdom) Alastair Riddell, CEO tim Allsopp, Chief Scientific Officer +44(0)1223-499160 Stem Cell Sciences p...

American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time

...der of endovascular simulation technology for this important project," said tim Shannon, VP of Sales and Marketing, Mentice Inc. "Team communication, when ..., M.D., Ph.D. 269-964-7850 william.hamman@wmich.edu Mentice Inc. tim Shannon 1-877-MENTICE usinfo@mentice.com ...

Stem Cell Sciences Announces the Creation of the World's First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology

...t: http://www.stemcellsciences.com . For further information, please contact: Stem Cell Sciences plc (United Kingdom), Alastair Riddell, CEO, tim Allsopp, Chief Scientific Officer, +44(0)1223-499160 Stem Cell Sciences LLC (United States), Rob Burgess, +1(0)214-440-2311 Stem Cell Sciences ...

CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

...edule including initiation of the Phase II breast cancer trial and accelerated enrollment of patients into the Phase II melanoma trial," commented Dr. tim Shannon, President and Chief Executive Officer of CuraGen. "Over the remainder of 2008, we look forward to completing enrollment in the melanoma study...

Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters

...e excited to have attracted someone of Abbie's caliber to Taligen at a time the company is moving rapidly toward the clinical development stage," said tim Mills, Ph.D., Taligen's chairman and a managing director with Sanderling Ventures. "I look forward to working with her as we implement our corporate g...

Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial

...uences. There are more than 500,000 sudden cardiac deaths in the US, and more than 300,000 in Europe, every year. The sudden and unexpected passing of tim Russert, host of NBC's Meet the Press, is thought to have been the result of a vulnerable plaque rupture. The SECRITT investigators plan to place th...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

...gs referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddock...

Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)

...der Replacement(TM) at the Annual Meeting of the American Urological Association (AUA) in Orlando, Florida on May 18, 2008. The data were presented by tim Bertram, D.V.M., Ph.D., Senior Vice President, Science and Technology of Tengion, during both a poster session and a press briefing sponsored by the A...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

...ings referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddock@n...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

...rred to above (or contained at the Internet links provided herein) is intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddock...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

...gs referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddock...

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

...cutive Officer (001) + 650 616 1902 Charles Thompson, Chief Financial Officer (001) + 650 616 1903 Buchanan Communications (44) + 020 7466 5000 tim Anderson, Mary-Jane Johnson About Napo Pharmaceuticals, Inc. Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprie...

Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

...s referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddock...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

...rtainties that are detailed in Nektar's reports and other filings with the SEC including its most recent Annual Report on Form 10-K. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddo...

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

...importantly, modulates the activity of specific brain regions during the performance of cognitive tasks relevant to Alzheimer's disease", commented Dr tim Tasker, Executive Vice President Clinical Development, Evotec AG. Dr Mitul Mehta, academic lead for the project at the Centre for Neuroimaging Scien...

Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction

...y undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddo...

Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer

...any's website or presented orally or visually through the Webcast is intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddo...

Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder

...tolerant or not adequately responsive to medical therapy. "OAB has a negative effect on the social and personal lives of those affected," stated Dr. tim Boone, Chair of Urology at The Methodist Hospital in Houston and a member of the Scott Department of Urology at Baylor College of Medicine. "Men and w...

Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA

...r patient infection rates. Legislation to establish a national infection reporting law has been introduced in Congress by lead sponsors Representative tim Murphy, R-PA., Representative Elijah Cummings, D-MD., and Senator Dick Durbin, D-IL. See: http://www.consumersunion.org/campaigns/Congressional%20Leg...

Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis

...ardie, Ph.D., David Rosen, Ph.D., Birthe Schnegelsberg, Ph.D., Mirella Lazarov, D.D.S, Ph.D., Robert Spiro, Ph.D. of Acologix, Harold Aberman, D.V.M., tim Simon, Ph.D. of Applied Biological Concepts. Presented by Dr. Middleton-Hardie on Friday, December 7 and Saturday, December 8, 2007, at the Osteoarthr...

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea

...cutive Officer (001) + 650 616 1902 Charles Thompson, Chief Financial Officer (001) + 650 616 1903 Buchanan Communications (44) + 020 7466 5000 tim Anderson, Mary-Jane Johnson About Napo Pharmaceuticals, Inc. Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprie...

Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health

...ited the recent CTLM installation at the Tianjin Medical University Cancer Institute and Hospital, where clinical studies are now underway. Explained tim Hansen, IMDS Chief Executive Officer: "Exhibiting at the Congress allowed us to support our global commercialization efforts while highlighting the re...

NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models

...meetings referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-7699 or sherrera@nektar.com Jennifer Ruddock (650) 631-4954 or jruddock@n...

Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers

... Center in Baltimore. "Esophageal cancer is as lethal as lung cancer and is one of the fastest growing cancers in the Western world right now," says tim Askew, president and CEO of CSA Medical. "More than 6 million people in the U.S. have Barrett's esophagus, while 65 million people suffer from GastroE...

Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference

...chnology can be a powerful platform for improving chemotherapeutic agents," tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "The new pre...intended to be incorporated by reference in this press release. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com Stephan Herrera (415) 488-76...

Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting

...nstipation, a serious and debilitating side effect of opioid therapy," said tim Riley, Ph.D. Vice President of PEGylation Research at Nektar. "This applica...er as a result of new information, future events, or otherwise. Contacts: tim Warner (650) 283-4915 or twarner@nektar.com ; Stephan Herrera (415) 488-7...

MUSC Research Offers Hope for Those Resistant to Depression Treatment

...ages of research as potential treatments for anxiety disorders, Alzheimer's disease, bulimia, chronic headache/migraine and morbid obesity. CONTACT: tim Gehret of Medical University of South Carolina,+1-843-792-2626 Web site: http://www.musc.edu/ Te...

Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial

...thKline, Organon and Wyeth. Contact: Stephanie Diaz (Investors) and tim Brons (Media) Vida Communication (On behalf of Pharmacopeia)...uture events, or otherwise. CONTACT: Investors, Stephanie Diaz, or Media, tim Brons, both of VidaCommunication, +1-415-675-7400, for Pharmacopeia Web s...

Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying to Control It Later

...a target="_blank" href= "mailto:pressoffice@lancet.com">pressoffice@lancet.com Please mention The Lancet as the source of this material Issued by tim Duffy, Acting North American Editorial and Press Coordinator, The Lancet Press pressoffice@l...

LANI completes Phase I in Japan and to commence Phase I in UK

...ilable at www.biota.com.au . Investor / Analyst Enquiries Media Enquiries Biota Holdings Limited tim Duncan or Nerida Mossop Peter Cook Hinton & Associates T: +61 3 9915 3720 T: +61 3 9600 1979 Damian Lismore M: +61 408 441 122 T: +61 3 9915 3...

Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference

...nsulin preparations, even though the standard type of inhaler used in this study was not optimized for delivery of insulin to the deep lung," said Dr. tim Heise, Profil Institut fur Stoffwechselforschung GmbH in Neuss, Germany, and principal investigator for the study. "RHIIP may have the potential to ac...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

...ging as a promising treatment option for patients who have active RRMS, or who are not responding optimally to traditional first-line therapies," said tim Vollmer, M.D., Director, Neuroimmunology Program, Barrow Neurological Institute at St. Joseph's Hospital and Medical Center and the primary investigat...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

...ging as a promising treatment option for patients who have active RRMS, or who are not responding optimally to traditional first-line therapies," said tim Vollmer, M.D., Director, Neuroimmunology Program, Barrow Neurological Institute at St. Joseph's Hospital and Medical Center and the primary investigat...
Other Tags
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... N.M. A credit-card-sized anthrax detection cartridge developed at ... business makes testing safer, easier, faster and cheaper. ... anthrax, is commonly found in soils all over the ... in both humans and animals. The bacteria can survive ... B. anthracis may occur through skin contact, ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
Other Contents